Increase of number of shares and votes in Vicore Pharma
Gothenburg, February 26, 2021– Vicore Pharma Holding AB (publ)’s (“Vicore Pharma”, or the “Company”) registered share capital and number of outstanding shares and votes have increased during the month of February 2021.
As previously announced, the Company’s board of directors resolved on November 2, 2020, by virtue of the authorization by the annual general meeting held on May 20, 2020, on an issue in kind to HaLaCore Pharma of 142,054 new shares at a subscription price of SEK 21.1 per share. The issue in kind is a down payment to HaLaCore Pharma for the acquisition of a series of intellectual property rights (IPR) as part of the development of novel angiotensin II type (AT2R) agonists.
As of today, the total number of registered and outstanding shares and votes of Vicore Pharma amounts to 60,560,293. Furthermore, the registered share capital amounts to SEK 30,280,146.
For further information, please contact:
Carl-Johan Dalsgaard, CEO, tel: +46 70 975 98 63, firstname.lastname@example.org
Hans Jeppsson, CFO, tel: +46 70 553 14 65, email@example.com
This information is information that Vicore Pharma Holding AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on February 26, 2021 at 09:00 CEST.
About Vicore Pharma Holding AB (publ)
Vicore is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has three drug development programs, VP01, VP02 and VP03. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”), pulmonary fibrosis in systemic sclerosis (“SSc”) and COVID-19. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need. VP03 includes follow-up molecules to VP01.
The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.